Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Common Equity (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Common Equity data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Common Equity fell 33.67% year-over-year to $5.9 million; the TTM value through Sep 2025 reached $5.9 million, down 33.67%, while the annual FY2024 figure was $7.3 million, 41.65% down from the prior year.
  • Common Equity reached $5.9 million in Q3 2025 per GANX's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $44.5 million in Q1 2021 and bottomed at $3.7 million in Q2 2025.
  • Average Common Equity over 5 years is $18.8 million, with a median of $12.6 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 63059.1% in 2021, then tumbled 68.64% in 2025.
  • A 5-year view of Common Equity shows it stood at $34.8 million in 2021, then plummeted by 45.78% to $18.9 million in 2022, then plummeted by 33.38% to $12.6 million in 2023, then plummeted by 41.65% to $7.3 million in 2024, then decreased by 19.49% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $5.9 million in Q3 2025, $3.7 million in Q2 2025, and $5.8 million in Q1 2025.